Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Equity Ratio (2016 - 2025)

Plus Therapeutics has reported Equity Ratio over the past 16 years, most recently at 0.24 for Q4 2025.

  • Quarterly Equity Ratio rose 118.14% to 0.24 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.24 through Dec 2025, up 118.14% year-over-year, with the annual reading at 0.24 for FY2025, 118.14% up from the prior year.
  • Equity Ratio was 0.24 for Q4 2025 at Plus Therapeutics, down from 0.27 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.6 in Q1 2022 and troughed at 1.96 in Q1 2025.
  • The 5-year median for Equity Ratio is 0.26 (2022), against an average of 0.02.
  • Year-over-year, Equity Ratio surged 12697.65% in 2021 and then tumbled 1039.78% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.49 in 2021, then tumbled by 45.22% to 0.27 in 2022, then tumbled by 143.83% to 0.12 in 2023, then crashed by 1039.78% to 1.35 in 2024, then soared by 118.14% to 0.24 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Equity Ratio are 0.24 (Q4 2025), 0.27 (Q3 2025), and 0.29 (Q2 2025).